Effect of pharmacological modulation of liver P-glycoproteins on cyclosporin A biliary excretion and cholestasis: A study in isolated perfused rat liver

Digestive Diseases and Sciences

Volumn 44, Issue 11, 1999, Pages 2196-2204

  Delle Monache, Marco ^a,b   Gigliozzi, Alessandro ^a,b   Benedetti, Antonio ^a,b   Marucci, Luca ^a,b   Bini, Adriano ^a,b   Francia, Chiara ^a,b   Papa, Emanuela ^a,b   Di Cosimo, Emanuele ^a,b   Fraioli, Flavia ^a,b   Jezequel, Anne Marie ^a,b   Alvaro, Domenico ^a,b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c NONE   (Italy)

Author keywords

Bile secretion; Cholestasis; Cyclosporin; P glycoproteins

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BILE SECRETION; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; DRUG EFFECT; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032707323     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026688200395     Document Type: Article

References (42)

1. 1. Kahan BD: Cyclosporin. N Engl J Med 321:1725-1738, 1989
2. 2. Dupont E: Immunological actions of corticosteroids and Cyclosporin A. Curr Opin Immunol 1:253-256, 1988
3. 3. Hess AD, Esa AH, Colombani PM: Mechanism of action of cyclosporin: Effect on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 20(suppl 2):29-40, 1988
4. 4. Kerman RH: Effect of cyclosporin immunosuppression in humans. Transplant Proc 20(suppl 2):143-152, 1988
5. 5. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, Dickson ER: A controlled trial of cyclosporin in the treatment of primary biliary cirrhosis. N Engl J Med 322:1419-1424, 1990
6. 6. Rodger RSC, Turney JH, Haines I, Michael J, Adu D, McMaster P: Cyclosporine and liver function in renal allograft recipients. Transplant Proc 4(S1):2754-2756, 1983
7. 7. Gulbis B, Adler M, Ooms HA, Desmet JM, Leclere JL, Primo G: Liver-function studies in heart-transplanted recipients treated with cyclosporin A. Clin Chem 34:1772-1774, 1988
8. 8. Rotolo FS, Branum GD, Bowers BA, Meyers WC: Effect of Cyclosporine on bile secretion in rats. Am J Surg 151:35-40, 1986
9. 9. Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A, Jimenez R: Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: Relationship with cholestasis and hyperbilirubinemia. Hepatology 12:83-91, 1990
10. 10. Galan AI, Roman ID, Munoz ME, Cava F, Gonzalez-Buitrago JM, Esteller A, Jimenez R: Inhibition of biliary lipid and protein secretion by cyclosporine in the rat. Biochem Pharmacol 44:1105-1113, 1992
11. 11. Bohme M, Muller M, Leier I, Jedlitschky G, Keppler D: Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salts transport in rat liver. Gastroenterology 107:255-265, 1994
12. 12. Stone B, Udani M, Sanghvi A, Warty V, Plocki K, Bedetti CD, Van Thiel DH: Cyclosporyn A-induced cholestasis: The mechanism in a rat model. Gastroenterology 93:344-351, 1987
13. 13. Le Thai B, Dumont M, Michel A, Erlinger S, Houssin D: Cholestalic effect of cyclosporine in the rat. Transplantation 46:510-512, 1988
14. 14. Kadmon M, Klunemann C, Bohme M, Ishikawa T, Gorgas K, Otto G, Herfarth C, Keppler D: Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from hepatocyte into bile. Gastroenterology 104:1507-1514, 1993
15. 15. Ptacheinski RJ, Venkataramanan R, Burekart GJ: Clinical Pharmacokinetics of cyclosporin. Clin Pharmacokin 11:107-132, 1986
16. 16. Fricker G, Fahr A: Mechanisms of hepatic transport of Cyclosporin A: an explanation for its cholestatic action? Yale J Biol Med 70:379-390, 1997
17. 17. Wolf A, Schramm U, Fahr A, Aicher L, Cordier A, Trommer WE, Fricker G: Hepatocellular effects of cyclosporine A and its derivative SDZ IMM 125 in vitro. J Pharmacol Exp Ther 284:817-825, 1998
18. 18. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199, 1990
19. 19. Foxwell BMJ. Mackie A, Ling V, Ryffel B: Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol Exp Ther 36:543-546, 1989
20. 20. Tamai I, Safa AR: Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 265:16509-16513, 1990
21. 21. Tamai I, Safa AR: Azidopine noncompetitively interacts with vinblastine and cyclosparin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266:16796-16800, 1991
22. 22. Takeguchi N, Ichimura K, Koike M, Malsui W, Kashiwagura T, Kawahara K: Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. Transplantation 55:646-650, 1993
23. 23. Saeki T, Ueda K, Tanigawara Y, Hori R, and Komano T: Human P-glycoprotein transports cyclosporin A and FK 506. J Biol Chem 268:6077-6080, 1993
24. 24. Schramm U, Fricker G, Wenger R, Miller D: P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. Am J Physiol 268:F46-F52, 1995
25. 25. Horton JK, Thimmaiah KN, Houghton JA, Horowitz ME, Houghton PJ: Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 38:1727-1736, 1989
26. 3H]vinblastine transport by isolated vesicles. Biochim Biophys Acta 1061:106-110, 1991
27. 27. Mayer U, Wagenaar E, Dorobeck B, Benijnen JH, Borst P, Schinkel AH: Full blockade of Intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100:2430-2436, 1997
28. 28. Watanabe T, Miyauchi S, Sawada Y, Iga T, Hanano M, Inaba M, Sugiyama Y: Kinetic analysis of hepatobiliary transport of vineristine in perfused rat liver. J Hepatol 16:77-88, 1992
29. 29. Gant TW, Silverman JA, Bisgaard HC, Burt RK, Marino PA, Thorgeirsson SS: Regulation of 2-Acetylaminofluorene-and 3-methylcholantnrene-mediated induction of multidrug resistance and cytochrome P-450IA gene family expression in primary hepatocyte cultures and rat liver. Mol Carcinog 4:499-509, 1991
30. 30. Schrenk D, Gant TW, Michalke A, Orzechowski A, Silverman JA, Battula N, Thorgeirsson SS: Metabolic activation of 2-acetylaminofluorene is equired for induction of multidrug resistance gene expression in rat liver cells. Carcinogenesis 15:2541-2546, 1994
31. 31. Bruck R, Benedetti A, Strazzabosco M, Boyer JL: Intracellular alkalinization stimulates bile flow and vesicular-mediated exocytosis in IPRL. Am J Physiol 28:G347-G353, 1993
32. 32. Alvaro D, Cho WK, Mennone A, Boyer JL: Effect of secretin on intracellular pH regulation in isolated rat bile duet epithelial cells. J Clin Invest 92:1314-1325, 1993
33. 3 exchanger in isolated rat hepatocyles: Role in regulation of intracellular pH. Am J Physiol 261:G512-G522, 1991
34. 34. Moran D, Gonzalez-Buitrago JM, Fernandez E, Galàn A, Munoz, ME, Jimenez R: Inhibition of biliary glutathione secretion by cyclosporine A in the rat: Possible mechanisms and role in the cholestasis induced by the drug. J Hepatol 29:68-77, 1998
35. 35. Debruyne D, Samba D, Lacotte J, Tartiere J, Deshayes JP, Segol P, Bricard H, Moulin M: Bile and blood ratios of cyclosporin and its melabolites in patients on continuous infusion during the first three weeks after liver transplantation. Clin Drug Invest 12:67-79, 1996
36. 36. Chan FHL, Zhang Y, Lee SS, Shaffer EA: The effects of liver transplantation and cyclosporine on bile formation and lipid composition: an experimental study in the rat. J Hepatol 28:329-336, 1998
37. 37. Schinkel AH, Wagenaar L, Van Deemter L, Mol CAAM, Borst P: Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705, 1995
38. 38. Sketris IS, Methot MR, Nicol D, Belitsky P, Knox M: Effect of calcium channel blockers on cyclosporine clearance and use in renal transplant patients, Ann Pharmacother 28:1227-1231, 1994
39. 39. Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with Cyclosporin. An update. Clin Pharmacokinet 30:141-179, 1996
40. 40. Arias IM: Cyclosporin, the biology of the bile canaliculus, and cholestasis. Gastroenterology 104:1558-1560, 1993
41. 41. Alvaro D, Gigliozzi A, Pial C, Carli L, Bini A, La Rosa T, Furfaro S, Capocaccia L: Effect of S-adenosyl-1-methionine on ethanol cholestasis and hepatoloxicity in isolated perfused rat liver. Dig Dis Sci 40(7):1592-1600, 1995
42. 42. Benedetti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, La Rosa T, Di Sario A, Baiocchi L, Jezequel AM: Cytotoxicity of bile salts against biliary epithelium: A study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 26:9-21, 1997